Investing in People and Medicine that Make a Difference

Investing in Medicine

Aescap Life Sciences is a biotech fund that invests in publicly traded biotech companies. It invests in high-growth, highly innovative companies that develop and market new medicines and, to a lesser extent, diagnostics and/or medical devices. Aescap Life Sciences has around 200 million euros under management and has an annualized net performance of around 16% over its five years of existence. Entry into and exit from this biotech fund is possible twice per month.

The biotech market is a large and fast-growing market. The substantial growth of the biotech market, also called life sciences market, is driven by an ageing population and an increased demand for ‘Western’ medicine in the emerging markets. After 30 years of development, groundbreaking technologies such as RNA, gene and cell therapies come to the market which often allow for more effective and safer medicines. These factors together are driving demand for improved and cost-effective medicine, diagnostics and medical devices. Since there are more than 1.000 public biotech companies, it is difficult to select those that will beat their competitors in the future. With over 30 years of experience investing in the life sciences market, Aescap Life Sciences enables investors to invest into the future winners of this industry. An investment in the fund will not only generate a good return on investment, it also supports the development of better treatments for diseases with a high unmet medical need such as ALS, Alzheimer’s, Arthritis, Cancer, MS, Obesity, Parkinson’s and many others.


Our net performance, since inception on March 28th 2016, is +120%, representing an annualized net IRR of around 16%, which is 53% above the return of the Nasdaq Biotech Index.

Get in touch

Our monthly presentation for existing and interested investors is currently replaced by a webcast. The next webcast will be held on July 7th at 15.00 cet.


Want to stay up to date?
Just subscribe to our newsletter here


    Aescap Life Sciences has a focused portfolio, investing in around 18 public biotech / life science companies. Most of the companies in our portfolio are based in Europe and the US. Our investment decisions are based on ‘high conviction’, fueled by thorough research and fundamental analyses. In the biotech sector such an analysis especially encompasses product portfolio patent protection, product development risks, market entry barriers, competition and the expected market development. But equally important are the serious efforts we undertake to understand the strengths and weakness of a company’s management, team dynamics, and their view on the future of the company and the markets they serve.

    Aescap Team

    5-star rating

    Morningstar has rated Aescap Life Sciences as a 5-star investment fund, the highest possible rating given. Morningstar’s rating has become the industry’s leading standard for determining a fund’s performance (risk/reward) relative to other funds. To rate a fund, Morningstar takes into account the long-term performance (3+ years) and only the top 10% best performing funds will receive a 5-star rating.
    See Aescap on Morningstar

    Latest News

    Aescap Life Sciences Quarterly Update Q1 2021

    Our portfolio companies delivered a series of value creating events, such as improved financials, approval of new products, profitable licensing deals and superior clinical study data. Despite these positive developments during Q1, our NAV ended the quarter at -3% due to stock markets being unfavorable for the biotech sector as a whole.

    Aescap 2.0 becomes Aescap Life Sciences

    After operating under the name Aescap 2.0 for almost 5 years, we feel our new name better represents our investment focus and the impact our companies have on the life of patients in need.

    Aescap 2.0 Quarterly Update Q4 2020

    Also for Aescap 2.0, 2020 was a roller coaster year. The fund was at an all-time high mid-February with a net performance of +5% for the year, after which it went down to -31% in mid-March, to then end the year at -3%.